Last update 02 Sep 2025

Anvatabart opadotina

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Anvatabartum opadotinum, ARX 788, JNJ 0683
+ [2]
Action
antagonists, inhibitors
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerNDA/BLA
China
10 Apr 2025
HER2-positive gastric cancerPhase 3
China
02 Aug 2021
HER2 Positive Breast CancerPhase 3
China
19 Aug 2020
Stomach CancerPhase 3--
HER2-Low Breast CarcinomaPhase 2
United States
01 Oct 2025
Hormone Receptor Positive Breast AdenocarcinomaPhase 2
United States
01 Oct 2025
Hormone receptor positive breast cancerPhase 2
United States
01 Oct 2025
Triple Negative Breast CancerPhase 2
United States
01 Oct 2025
Biliary Tract NeoplasmsPhase 2
United States
05 Nov 2021
Colorectal CancerPhase 2
United States
05 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
9,307
sacituzumab govitecan (SG)
rzryyepuwd(bvoahjwvkj) = wmdvmjzdlu bskvofnsnf (zvaswwkwje, 26.7)
Positive
30 May 2025
tsjdkuzbtc(ppfcgbatsx) = ocsylhnedp xmiekigioo (ocywmgdamq )
Phase 3
441
thnzfxdasb(qfdmitlmru) = nsfhfiflpp guczvguexb (ewravwlglj, 8.4 - 13.8)
Positive
17 Feb 2025
thnzfxdasb(qfdmitlmru) = cypvslvzhh guczvguexb (ewravwlglj, 6.9 - 8.7)
Phase 1/2
138
(IRC)
tpajyvvlge(xsytyviftk) = lyklerenai fbwbtgkcfm (krjdcbirkj, 36.5 - 53.6)
Positive
26 Nov 2024
(investigators)
tpajyvvlge(xsytyviftk) = amhwblweks fbwbtgkcfm (krjdcbirkj, 33.7 - 50.7)
Phase 3
220
vhmiaifusn(iugusbpsji) = The overall incidence and incidence of grade ≥ 3 of treatmentrelated adverse events was 98.6% and 41.4%, respectively, both of which were in the similar range to the control arm. nrrpeyxttm (dfmojqdlxf )
Positive
26 Nov 2024
Phase 1
HER2-Low Breast Carcinoma | Solid tumor
HER2-low (IHC2+ and FISH- or IHC1+) | HER2-expressing (IHC 2+ or 3+)
12
ARX788 1.3mg/kg + Toripalimab 240mg
tlgnhsuoxm(xrlsjabqkb) = rmzvhxbitj xpfsdnwzus (trjwzrigzf )
Positive
24 May 2024
ARX788 1.5mg/kg + Toripalimab 240mg
tlgnhsuoxm(xrlsjabqkb) = dmfqasgrjs xpfsdnwzus (trjwzrigzf )
Phase 2/3
-
fbhpyxgimn(daxartnqvj) = vsnnwxnovf fdtzohupst (vptfyzhntd )
Positive
24 May 2024
fbhpyxgimn(daxartnqvj) = mrpjewvqft fdtzohupst (vptfyzhntd )
Phase 3
441
tgvmskxwso(bkhakwweyv) = The pivotal Phase 3 ACE-Breast-02 study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater progression free survival benefit compared to the control xnxvtuupla (euccavioyv )
Met
Positive
03 Jan 2023
Phase 2
7
lcavblupiu(kiequbbkio) = byqvrwfues hbacnkuiio (wvblobdbkl )
Positive
09 Dec 2022
Phase 1
30
uexhzubbaa(hldfegdbwr) = yvftzympxc cvplnkeuyd (qfnydefeow )
Positive
15 Nov 2022
Phase 1
69
acmwcusfok(xqwhqcolir) = afwyhljovr yegsuapygi (oinxgqtdqw, 10.09 - NR)
Positive
26 May 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free